Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.58 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | SAE1 | Q9UBE0 | 3/20 | 0.53 |
| ▸ | UBA2 | Q9UBT2 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762349 | 0.94 | POLB (0.62) | SLC1A3SLC1A2SLC1A1POLBCA1 | |
| Phenol SCHEMBL663964 | 0.90 | MAOA (0.53) | SLC1A3SLC1A2SLC1A1POLBCA1 | |
| SCHEMBL28945385 | 0.84 | ALDH1A1 (0.53) | POLBLMNAMEN1KMT2AHTT | |
| SCHEMBL4683087 | 0.84 | MAPT (0.55) | SLC1A3SLC1A2SLC1A1POLBCA1 | |
| SCHEMBL11244794 | 0.84 | PTPN1 (0.70) | SLC1A3SLC1A2SLC1A1POLBLMNA | |
| SCHEMBL6436840 | 0.84 | HDAC8 (0.56) | POLBEPHX2MEN1KMT2APTPN1 | |
| SCHEMBL11788375 | 0.84 | SLC1A3 (0.55) | SLC1A3SLC1A2SLC1A1POLBCA1 | |
| SCHEMBL8859893 | 0.84 | GAA (0.63) | SLC1A3SLC1A2SLC1A1POLBCA1 | |
| SCHEMBL2891493 | 0.83 | SMN1; SMN2 (0.71) | POLBCA1CA2CA9CA12 | |
| SCHEMBL21504845 | 0.82 | CA1 (0.57) | SLC1A3SLC1A2SLC1A1POLBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443092-B1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
| EP-0014103-B1 | IMPROVED PROCESS FOR THE MANUFACTURE OF CARBAMATES | THE HALCON SD GROUP, INC. (US) | 1983-05-11 | — | — | EP | disclosed |
| US-4279637-A | Herbicidal N-substituted 4-imidazolin-2-ones | VELSICOL CHEMICAL CORPORATION (US) | 1981-07-21 | — | — | US | disclosed |
| US-4266070-A | CARBONYLS OF COBALT, MOLYBDENUM, TITANIUM, RHODIUM, IRON, NICKEL AND IRIDIUM AS CATALYSTS FOR THE CARBONYLATION OF PRIMARY OR SECONDARY AMINES AND ALCOHOLS TO FORM CARBAMATES | HALCON RESEARCH AND DEVELOPMENT CORP. (US) | 1981-05-05 | — | — | US | disclosed |
| US-4260781-A | Process for the manufacture of carbamates | HALCON RESEARCH AND DEVELOPMENT CORP. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4258201-A | CATALYTIC CARBONYLATION OF PRIMARY OR SECONDARY AMINES WITH CARBON MONOXIDE AND ALCOHOLS | HALCON RESEARCH AND DEVELOPMENT CORP. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4242520-A | ONE-STEP CARBONYLATION OF AMINES IN THE PRESENCE OF A DISULFIDE | HALCON RESEARCH & DEVELOPMENT CORPORATION (US) | 1980-12-30 | — | — | US | disclosed |
| EP-0014103-A2 | Improved process for the manufacture of carbamates | THE HALCON SD GROUP, INC. (US) | 1980-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | SLC1A3 1316/4885SLC1A2 312/4885SLC1A1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.